Elicin Olgun, Koller Brolese Eliane, Bojaxhiu Beat, Sermaxhaj Burim, Schanne Daniel Hendrik, Mathier Etienne, Lippmann Jana, Shelan Mohamed, Eller Yannick, Aebersold Daniel Matthias, Giger Roland, Cihoric Nikola
Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Radiother Oncol. 2021 May;158:293-299. doi: 10.1016/j.radonc.2021.04.004. Epub 2021 Apr 20.
The potential impact of daytime and season of radiotherapy application on prognosis is unclear. This was analyzed in a retrospective cohort of patients who were diagnosed with non-metastatic head and neck squamous cell carcinoma (HNSCC) and treated with definitive radiotherapy with or without chemotherapy.
Patient and tumor characteristics, treatment parameters and outcome until last follow-up or death were obtained. Median radiotherapy delivery daytime of each patient was categorized as morning (AM) and afternoon (PM). Treatment season was defined by median date of treatment course. Each year was divided into DARK and LIGHT according to equinoxes. Time-to-event endpoints were defined by first biopsy confirming the HNSCC.
Six hundred fifty-five cases were identified who were treated with (chemo)radiotherapy between 2002 and 2015. Median follow-up was 47 months. No significant heterogeneity in patient, tumor and treatment characteristics were observed between DARK and LIGHT or regarding median daily fraction time (X2 p > 0.05). Five-year loco-regional control (73% vs. 61%; p = 0.0108) and progression-free survival (51% vs. 43%; p = 0.0374) were superior when radiotherapy was administered in DARK. Neither the daytime nor any other treatment time-related parameter affected prognosis.
This is the first study investigating and presenting the prognostic impact of seasonality regarding the treatment course on loco-regional control and progression-free survival (DARK > LIGHT). The biological mechanism of action is unclear. These results should be interpreted with caution and our findings have to be validated externally.
放射治疗的日间时间和季节对预后的潜在影响尚不清楚。在一组回顾性队列研究中对这一问题进行了分析,该队列中的患者被诊断为非转移性头颈部鳞状细胞癌(HNSCC),并接受了单纯放疗或放化疗。
获取患者和肿瘤特征、治疗参数以及直至最后一次随访或死亡的结果。将每位患者放疗的中位日间时间分为上午(AM)和下午(PM)。治疗季节由疗程的中位日期确定。根据二分点将每年分为黑暗期和光明期。事件发生时间终点由首次活检确诊HNSCC来定义。
确定了655例在2002年至2015年间接受(放)化疗的病例。中位随访时间为47个月。在黑暗期和光明期之间,或关于每日分割时间中位数方面,未观察到患者、肿瘤和治疗特征存在显著异质性(X2 p > 0.05)。当在黑暗期进行放疗时,5年局部区域控制率(73%对61%;p = 0.0108)和无进展生存率(51%对43%;p = 0.0374)更高。日间时间和任何其他与治疗时间相关的参数均未影响预后。
这是第一项研究并呈现治疗疗程的季节性对局部区域控制和无进展生存率的预后影响的研究(黑暗期>光明期)。其生物学作用机制尚不清楚。这些结果应谨慎解读,我们的发现必须在外部得到验证。